

Medicare Advantage Drugs/Biologics Part B  
Prior Authorization Form



Part B Step Therapy – Stelara IV, Imuldosa IV, Otulfi IV, Pyzchiva IV, Starjemza IV, Steqeyma IV, Ustekinumab (unbranded Stelara) IV, Ustekinumab-ttwe IV, Wezlana IV, Yesintek IV

This form applies to all HealthSpring Medicare Advantage markets. It does not apply to Medicaid only and Medicare-Medicaid Plans (MMP). Please fax to **877-730-3858** | Phone: **888-454-0013**

To ensure your request is processed in a timely manner, please submit all pertinent clinical information.

<input type="checkbox"/> Expedited – defined as danger to a member’s health if not provided within 24 hours		
Member name		Member date of birth
Requesting provider		Member ID
Contact person		Date of service
Address		
NPI	Phone	Fax

If referring to a servicing provider, the information below must be submitted.	
Servicing provider	Phone
Contact person	Fax
Address	NPI
<input type="checkbox"/> Check here if servicing provider is out of network. Please explain.	
Who will supply the medication? <input type="checkbox"/> Provider office <input type="checkbox"/> Outpatient hospital/clinic <input type="checkbox"/> Pharmacy not located within the servicing facility	Please select place of service by checking only one of the boxes <input type="checkbox"/> Provider office <input type="checkbox"/> Outpatient hospital/clinic <input type="checkbox"/> Other. Please specify _____
Diagnosis codes	Diagnosis

Please attach all required documentation: recent clinical notes, copy of the prescription or provider order, and relevant diagnostic lab results.				
HCPCS codes	Drug (if applicable)	Dose (if applicable)	Frequency	Duration
Is this a new start or a continuation of therapy within the past 365 days?				
Has the member had an intolerance or an inadequate response to Step 1 alternative Selarsdi IV, Ustekinumab aekn IV?*				
If the member is unable to try Step 1 alternative Selarsdi IV, Ustekinumab aekn IV, please provide the reason(s) an exception should be made to the step therapy requirement.				

\*HealthSpring requires prior authorization for Step 1 alternative – Selarsdi IV, Ustekinumab aekn IV.